hydrazine has been researched along with Peripheral Nerve Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Anderson, LD; Auner, HW; Bahlis, NJ; Beaumont, JL; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Facon, T; Garg, MK; Grosicki, S; Hájek, R; Hudgens, S; Illmer, T; Jagannath, S; Kauffman, M; Kriachok, I; Leleu, X; Leong, H; Levy, M; Ma, X; Pour, L; Quach, H; Richardson, P; Sanchez, L; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Tang, S; Usenko, G; Venner, C; Yu, H | 1 |
| Astruc-Diaz, F; Craig, S; Diaz, P; Munoz, E; Naguib, M; Xu, JJ | 1 |
| Carroll, WA; Donnelly-Roberts, DL; Faltynek, CR; Grayson, G; Harris, R; Honore, P; Jarvis, MF; Kalvin, DM; Namovic, MT; Nelson, DW; Sarris, K | 1 |
| Harati, Y; Niakan, E | 1 |
1 trial(s) available for hydrazine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Triazoles | 2021 |
4 other study(ies) available for hydrazine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Female; Frailty; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Triazoles | 2021 |
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Topics: Animals; Behavior, Animal; Biotransformation; Cannabinoids; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Hydrazines; Indoles; Male; Mice; Mice, Knockout; Paclitaxel; Pain; Pain Measurement; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Spinal Nerves | 2010 |
Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists.
Topics: Analgesics; Animals; Calcium; Cell Line; Humans; Hydrazines; Interleukin-1beta; Isoquinolines; Pain; Pain Measurement; Peripheral Nervous System Diseases; Peritoneal Cavity; Peritonitis; Purinergic P2 Receptor Antagonists; Quinolines; Rats; Receptors, Purinergic P2X7; Recombinant Proteins; Structure-Activity Relationship | 2008 |
Hydrazine toxicity, pyridoxine therapy, and peripheral neuropathy.
Topics: Adult; Humans; Hydrazines; Male; Peripheral Nervous System Diseases; Pyridoxine | 1986 |